Jerini Overview
- Founded
-
1984
- Status
-
Acquired/Merged
- Employees
-
65
- Latest Deal Type
-
M&A
- Financing Rounds
-
4
Jerini General Information
Description
Developer and marketer of peptide-based drugs. The company offers Firazyr (Icatibant) for the treatment of acute attacks of hereditary angioedema. Its developing product pipeline includes JSM 6427, a a5ß1 Integrin antagonist for the treatment of cancer, age-related mascular degeneration-blindness in the elderly, and angiogenesis, inflammation, and fibrosis; and JSM-7717 and JPE-1375, which are C5a receptor antagonists for the treatment of inflammatory and ophthalmological diseases.
Contact Information
Primary Office
- Invalidenstrasse 130
- 10115 Berlin
- Germany
Jerini Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Jerini Patents
Jerini Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2752190-A1 | Small molecule bradykinin b1 receptor antagonists | Abandoned | 13-Feb-2009 | 0000000000 | |
| EP-2396301-A2 | Small molecule bradykinin b1 receptor antagonists | Withdrawn | 13-Feb-2009 | 0000000000 | |
| EP-2344477-A1 | Small molecule bradykinin b2 receptor modulators | Withdrawn | 22-Sep-2008 | 0000000000 | |
| EP-2344176-A1 | Use of bradykinin b1 receptor antagonists in intestinal fibrosis treatment | Withdrawn | 18-Sep-2008 | 0000000000 | |
| JP-2009536961-A | Novel heterocyclic compounds inhibiting integrins and uses thereof | Pending | 12-May-2006 | C07D405/12 |
Jerini Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Jerini Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|